Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 3Neoplasms 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Glioma 1Cancer Related Cognitive Decline 1Brain Neoplasms 1

Interventions

Pemetrexed 8Spinal Puncture 5Specimen Handling 4Radiotherapy 4Magnetic Resonance Spectroscopy 4aflutinib 3Trastuzumab 3Bevacizumab 3trastuzumab deruxtecan 2pembrolizumab 2osimertinib 2Radiotherapy, Intensity-Modulated 2tucatinib 1toripalimab 1sintilimab 1sacituzumab govitecan 1pertuzumab 1peginterferon alfa-2b 1lorlatinib 1lenvatinib 1azeliragon 1avelumab 1adavosertib 1Temozolomide 1Referral and Consultation 1Radiosurgery 1Radiation 1Probability 1Physical Examination 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Meningeal Carcinomatosis × azeliragon × 1 year × Clear all
NCT06724926 2026-05-18

Concurrent Azeliragon With Craniospinal Irradiation

NYU Langone Health

Phase 1 Active not recruiting
21 enrolled
CNS

Glioma, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡